What is PBS Biotech?
Founded in 2006 and headquartered in Camarillo, California, PBS Biotech is dedicated to becoming a premier provider of scalable, single-use bioreactor systems. Their proprietary Vertical-Wheel™ technology is engineered to ensure homogenous mixing and minimize shear stress, facilitating the uniform suspension of aggregates or micro-carriers. This advanced technology aims to empower customers in delivering safe, effective, and high-value cell-based therapies to millions of patients worldwide, positioning PBS Biotech at the forefront of the biopharmaceutical tools and services sector.
How much funding has PBS Biotech raised?
PBS Biotech has raised a total of $50M across 5 funding rounds:
Debt
$350K
Debt
$669K
Private Equity
$10M
Unspecified
$22M
Other Financing Round
$17M
Debt (2020): $350K with participation from PPP
Debt (2021): $669K led by PPP
Private Equity (2021): $10M supported by BroadOak Capital Partners
Unspecified (2023): $22M featuring BroadOak Capital Partners
Other Financing Round (2025): $17M backed by BroadOak Capital Partners and Avego
Key Investors in PBS Biotech
BroadOak Capital Partners
BroadOak Capital Partners is a boutique financial institution specializing in direct investment and banking services for life sciences and biopharma services companies. They focus on life sciences tools, diagnostics, and biopharma services, leveraging their expertise and networks to deliver results.
Avego
Avego is a multi-strategy investment firm dedicated to the healthcare sector, aiming to combine industry expertise and capital with entrepreneurial management to enhance patient outcomes. They invest in private and public companies innovating in healthcare.
PPP
Public-Private Partnership
What's next for PBS Biotech?
The substantial enterprise-level capital infusion signifies a critical phase of scaling for PBS Biotech. With a clear focus on advancing its single-use bioreactor technology, the company is poised to expand its market reach and enhance its manufacturing capabilities. The strategic backing from key investors suggests a strong market validation for their innovative approach to stem cell therapy production. Future developments will likely concentrate on further refining their technology, increasing production capacity, and forging strategic partnerships to broaden access to their life-saving solutions.
See full PBS Biotech company page
